Global Ketolides Market, By Indication (Bronchitis, Pneumonia, Sinusitis, Tonsillitis/Pharyngitis), Drug Type (Telithromycin, Cethromycin, Solithromycin), Microorganism (Streptococcus Pneumoniae, Haemophilus Influenzae, Moraxella Catarrhalis, Chlamydophila Pneumoniae, and Mycoplasma Pneumoniae), Population Type (Children and Adults), Disease Type (Mild and Severe), Dosage Type (Oral and Parenteral), Mode of Purchase (Over the Counter and Prescription), End User (Hospitals, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) – Industry Trends and Forecast to 2030.
Ketolides Market Analysis and Size
Ketolides are known to have immunomodulatory and anti-inflammatory effects that are used for many health conditions. The increase in the incidence of infectious diseases is increasing the market's growth. Many of the developed economies, such as the U.S., Japan, and countries of Western Europe, have a huge set of the elderly population that is more susceptible to numerous bacterial infections, primarily which is caused by low immunity. Also, ketolide is more useful than other antibacterial drugs for treating several conditions, further enhancing the market.
Data Bridge Market Research analyses that the ketolides market, which was USD 3 billion in 2022, would rise to USD 4.11 billion by 2030 and is expected to undergo a CAGR of 4% from 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Ketolides Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Indication (Bronchitis, Pneumonia, Sinusitis, Tonsillitis/Pharyngitis), Drug Type (Telithromycin, Cethromycin, Solithromycin), Microorganism (Streptococcus Pneumoniae, Haemophilus Influenzae, Moraxella Catarrhalis, Chlamydophila Pneumoniae, and Mycoplasma Pneumoniae), Population Type (Children and Adults), Disease Type (Mild and Severe), Dosage Type (Oral and Parenteral), Mode of Purchase (Over the Counter and Prescription), End User (Hospitals, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
|
|
Countries Covered
|
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Abbott (U.S.), Alembic Pharmaceuticals Limited (India)., WOCKHARDT.( India)
|
|
Market Opportunities
|
|
Market Definition
Ketolides are a new class of semisynthetic agents derived from erythromycin A, specifically designed to overcome macrolide resistance against S. pneumoniae. These antibiotics are effective against gram-positive bacteria and intracellular pathogens, such as mycoplasma, chlamydia, and legionella. The main clinical indication for ketolide is the treatment of community-acquired, mild to moderate, upper and lower respiratory tract infections.
Global Ketolides Market Dynamics
Drivers
- Increasing Prevalence of Infectious Diseases
The increasing incidence of infectious diseases leads to market growth. The nationwide prevalence of all infectious disease syndromes was 71.8 per 10,000 people between 2009 and 2017. The average number of all infectious diseases was around 14,519 (range 5229 to 55,132) every year. This increasing prevalence of infectious diseases leads to the higher adoption of ketolides, leading to the growth of the market.
- Increasing Demand for Telithromycin
The increasing demand for telithromycin is helping the market grow. Telithromycin has a good range of activity against respiratory pathogens, which includes intracellular bacteria, penicillin-resistant, erythromycin-resistant pneumococci, and atypical bacteria. It has a type of oral availability of 57% in young and elderly people, and the rate and extent of absorption are unaffected by food. Thus, this factor boosts market growth.
Opportunities
- Increasing R&D Activities by Market Players
Various drugs are developing, and some are launched, boosting the market growth. For instance, cethromycin is a once-daily ketolide that originated from research by Abbott Laboratories. There have been few studies on cethromycin so far. Therefore, this factor is a major factor that increases market growth.
Restraints/Challenges
- Side Effects of Ketolides
Various side-effects are associated with ketolides that hamper the market growth. Common side effects of ketolides are nausea, diarrhea, and vomiting. Telithromycin has been related to potentially fatal hepatotoxicity and should be avoided in patients with hepatic dysfunction. The U.S. Food and Drug Administration (FDA) announced a black box warning specifying that telithromycin should not be used in patients suffering from myasthenia gravis. Thus, this leads to market hindrance.
This ketolides market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the ketolides market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Ketolides Market Scope
The ketolides market is segmented on the basis of indication, drug type, microorganism, population type, disease type, mode of purchase, dosage type, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Bronchitis
- Pneumonia
- Sinusitis
- Tonsillitis/Pharyngitis
Drug Type
- Telithromycin
- Cethromycin,
- Solithromycin
Microorganism
- Streptococcus Pneumoniae
- Haemophilus Influenzae
- Moraxella Catarrhalis
- Chlamydophila Pneumoniae
- Mycoplasma Pneumoniae
Population Type
- Children
- Adults
Disease Type
- Mild
- Severe
Dosage Type
- Oral
- Parenteral
Mode of Purchase
- Over the Counter
- Prescription
End User
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Ketolides Market Regional Analysis/Insights
The ketolides market is analyzed and market size insights and trends are provided by indication, drug type, microorganism, population type, disease type, mode of purchase, dosage type, end user, and distribution channel, as referenced above.
The countries covered in the ketolides market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to grow during the forecast period of the ketolides market because of the increase in infectious diseases in this region and the higher prescription rate in these regions.
North America dominates the market in the forecast period because of the increase in the incidence of bacterial skin infection within the region. The U.S. holds a huge portion of the market in North America compared to other countries in the region due to developed healthcare infrastructure, increased awareness, and increased research and development.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The ketolides market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for ketolides market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the ketolides market. The data is available for historic period 2011-2021.
Competitive Landscape and Global Ketolides Market Share Analysis
The ketolides market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to ketolides market.
Some of the major players operating in the ketolides market are:
- F. Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- Eli Lilly and Company (U.S.)
- Pfizer Inc. (U.S.)
- Merck & Co., Inc. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Abbott (U.S.)
- Alembic Pharmaceuticals Limited (India).
- WOCKHARDT. (India)
SKU-